Almirall S.A
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism; antiinfecti… Read more
Almirall S.A (LBTSF) - Net Assets
Latest net assets as of June 2025: $1.46 Billion USD
Based on the latest financial reports, Almirall S.A (LBTSF) has net assets worth $1.46 Billion USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.31 Billion) and total liabilities ($844.82 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.46 Billion |
| % of Total Assets | 63.39% |
| Annual Growth Rate | 2.69% |
| 5-Year Change | 14.23% |
| 10-Year Change | 1.76% |
| Growth Volatility | 28.28 |
Almirall S.A - Net Assets Trend (2005–2024)
This chart illustrates how Almirall S.A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Almirall S.A (2005–2024)
The table below shows the annual net assets of Almirall S.A from 2005 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.49 Billion | +1.71% |
| 2023-12-31 | $1.46 Billion | +10.97% |
| 2022-12-31 | $1.32 Billion | +2.54% |
| 2021-12-31 | $1.29 Billion | -1.30% |
| 2020-12-31 | $1.30 Billion | +1.78% |
| 2019-12-31 | $1.28 Billion | +7.42% |
| 2018-12-31 | $1.19 Billion | +5.12% |
| 2017-12-31 | $1.13 Billion | -25.43% |
| 2016-12-31 | $1.52 Billion | +3.94% |
| 2015-12-31 | $1.46 Billion | +9.18% |
| 2014-12-31 | $1.34 Billion | +50.80% |
| 2013-12-31 | $888.33 Million | -3.83% |
| 2012-12-31 | $923.67 Million | +8.07% |
| 2011-12-31 | $854.71 Million | +4.32% |
| 2010-12-31 | $819.30 Million | +9.09% |
| 2009-12-31 | $751.00 Million | -- |
| 2008-12-31 | $0.00 | -- |
| 2007-12-31 | $573.65 Million | -24.84% |
| 2006-12-31 | $763.21 Million | -15.06% |
| 2005-12-31 | $898.52 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Almirall S.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 91.4% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $10.15 Million | 0.68% |
| Common Stock | $25.62 Million | 1.72% |
| Other Components | $1.45 Billion | 97.60% |
| Total Equity | $1.49 Billion | 100.00% |
Almirall S.A Competitors by Market Cap
The table below lists competitors of Almirall S.A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aprilbio Co. Ltd.
KQ:397030
|
$678.93 Million |
|
Shenzhen Newway Photomask Making Co. Ltd. A
SHG:688401
|
$679.21 Million |
|
Xiamen Anne Corp Ltd
SHE:002235
|
$679.45 Million |
|
Zhejiang Construction Investment Group Co Ltd
SHE:002761
|
$679.46 Million |
|
Hangzhou Steam Turbine
SHE:200771
|
$678.61 Million |
|
Equitas Small Finance Bank Limited
NSE:EQUITASBNK
|
$678.10 Million |
|
Wereldhave N.V
PINK:WRDEF
|
$678.07 Million |
|
Xinhuanet Co Ltd
SHG:603888
|
$677.99 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Almirall S.A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,463,400,000 to 1,488,382,000, a change of 24,982,000 (1.7%).
- Net income of 10,147,000 contributed positively to equity growth.
- Dividend payments of 3,288,000 reduced retained earnings.
- New share issuances of 539,000 increased equity.
- Other comprehensive income decreased equity by 895,265,000.
- Other factors increased equity by 912,849,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $10.15 Million | +0.68% |
| Dividends Paid | $3.29 Million | -0.22% |
| Share Issuances | $539.00K | +0.04% |
| Other Comprehensive Income | $-895.26 Million | -60.15% |
| Other Changes | $912.85 Million | +61.33% |
| Total Change | $- | 1.71% |
Book Value vs Market Value Analysis
This analysis compares Almirall S.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.28x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.67x to 1.28x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $5.41 | $9.01 | x |
| 2006-12-31 | $4.59 | $9.01 | x |
| 2007-12-31 | $3.45 | $9.01 | x |
| 2008-12-31 | $4.02 | $9.01 | x |
| 2009-12-31 | $4.51 | $9.01 | x |
| 2010-12-31 | $4.93 | $9.01 | x |
| 2011-12-31 | $5.15 | $9.01 | x |
| 2012-12-31 | $5.33 | $9.01 | x |
| 2013-12-31 | $5.14 | $9.01 | x |
| 2014-12-31 | $7.75 | $9.01 | x |
| 2015-12-31 | $8.46 | $9.01 | x |
| 2016-12-31 | $8.79 | $9.01 | x |
| 2017-12-31 | $6.54 | $9.01 | x |
| 2018-12-31 | $6.34 | $9.01 | x |
| 2019-12-31 | $6.81 | $9.01 | x |
| 2020-12-31 | $6.90 | $9.01 | x |
| 2021-12-31 | $7.19 | $9.01 | x |
| 2022-12-31 | $7.30 | $9.01 | x |
| 2023-12-31 | $7.43 | $9.01 | x |
| 2024-12-31 | $7.04 | $9.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Almirall S.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.68%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.03%
- • Asset Turnover: 0.41x
- • Equity Multiplier: 1.61x
- Recent ROE (0.68%) is below the historical average (8.07%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 13.10% | 15.99% | 0.61x | 1.34x | $27.87 Million |
| 2006 | 19.29% | 18.58% | 0.71x | 1.46x | $70.93 Million |
| 2007 | 22.87% | 15.38% | 0.59x | 2.51x | $73.84 Million |
| 2008 | 20.84% | 15.08% | 0.65x | 2.14x | $70.80 Million |
| 2009 | 20.17% | 16.37% | 0.62x | 1.97x | $76.40 Million |
| 2010 | 14.48% | 13.44% | 0.57x | 1.88x | $36.67 Million |
| 2011 | 9.85% | 10.95% | 0.53x | 1.70x | $-1.31 Million |
| 2012 | 8.26% | 10.67% | 0.53x | 1.47x | $-16.08 Million |
| 2013 | -3.80% | -4.51% | 0.42x | 2.00x | $-122.55 Million |
| 2014 | 33.48% | 54.75% | 0.32x | 1.90x | $314.47 Million |
| 2015 | 9.01% | 19.13% | 0.27x | 1.73x | $-14.43 Million |
| 2016 | 4.96% | 9.87% | 0.27x | 1.85x | $-76.55 Million |
| 2017 | -26.81% | -47.54% | 0.29x | 1.92x | $-417.33 Million |
| 2018 | 6.52% | 10.26% | 0.32x | 2.01x | $-41.50 Million |
| 2019 | 8.27% | 12.38% | 0.35x | 1.91x | $-22.11 Million |
| 2020 | 5.70% | 4.60% | 0.70x | 1.76x | $-56.02 Million |
| 2021 | -3.18% | -4.94% | 0.39x | 1.67x | $-169.46 Million |
| 2022 | 0.32% | 0.50% | 0.40x | 1.63x | $-127.59 Million |
| 2023 | -2.63% | -4.30% | 0.38x | 1.62x | $-184.81 Million |
| 2024 | 0.68% | 1.03% | 0.41x | 1.61x | $-138.69 Million |
Industry Comparison
This section compares Almirall S.A's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Almirall S.A (LBTSF) | $1.46 Billion | 13.10% | 0.58x | $678.91 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |